巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Omeros Corp

    OMER
    2.810
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Omeros Corp - 延遲價格・最後更新於 23/05 1:21
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    2.810
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    2.660
    賣出
    3.100
    每手股數
    --
    市值(百萬)
    176.27
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    16.620 - 2.500
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Omeros Corp
    證券代碼
    OMER.US
    所屬板塊
    Biotechnology
    公司業務
    Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
    發行量
    62726515
    公司總部
    201 Elliott Avenue West
    公司網址
    https://www.omeros.com
    公司電話
    +1 206 676-5000
    暫無內容

    關於

    Omeros Corp(OMER.US)所屬的行業板塊為Biotechnology。
    Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
    詳細公司背景可參考: https://www.omeros.com